In light of these limitations, further large-scale studies with more homogeneous cohorts, incorporating medication tracking, and longitudinal follow-up are necessary to validate the current results and clarify the mechanistic and prognostic roles of FGF-2, FGF-19, FGF-22, and FGF-23 in diabetes. The gene discussed is FGF22; the disease is diabetes mellitus.